Direct-to-Consumer (DTC) Drug Advertisements, Part Three

March 21, 2016

FDA’s Proposed Study on Consumer Understanding of Quantitative Information in DTC Drug Ads

In October 2015, the FDA announced plans to conduct a study which would determine how much quantitative information consumers can actually handle in television advertisements for prescription drugs.

In its announcement, the FDA acknowledged that previous research has been conducted on the topic, which concluded that “simple quantitative information could be conveyed in DTC television ads in ways that increased consumer’s knowledge about the drug.” The previous study only tested consumers’ understanding of simple drug information; and as many people know, drug information can sometimes be extremely complicated. As such, FDA designed two studies that would determine “whether consumers can use more complicated information when assessing prescription drug information in television DTC ads.”

As part of this October 2015 announcement, FDA requested feedback from the public and asked any interested parties to submit comments on the proposed study. FDA received four public comments in response to this request, along with a number of other comments which were not submitted publicly. On Friday, March 18, 2016, the FDA published a notice in the Federal Register which included the additional comments that were submitted as well as the Agency’s responses.

Additional information on the specific comments and the accompanying responses can be found in the Federal Register notice.

ProPharma has significant expertise in working through advertising compliance issues. To discuss this or any other FDA-related matter, contact us today.


October 1, 2015

Will FDA Change the Definition of “Intended Use”?

FDA released proposed regulation that would allow sponsors to determine if their product is a drug/device, or if it is not a drug/device. Last week, the Agency announced a proposed rule “to provide...

March 31, 2015

Drug Development Questions And The FDA - The End Of The Black Hole

Commonly during drug development, significant issues arise for which FDA input is desired but that do not merit a full face-to-face multidisciplinary milestone meeting. In many cases, sponsors are...

May 31, 2016

FDA Approves Implant Device to Treat Opioid Addiction

On Thursday, May 26th, FDA announced the approval of Probuphine® , a buprenorphine implant for the treatment of opioid dependence. The implant is the first device of its kind, and “is designed to...